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Introduction: MicroRNAs (miRNA) are small non-coding RNAs that play an important role in the control of gene
expression by inhibiting protein translation or promoting messenger RNA degradation. Today, miRNAs have
been shown to be involved in various physiological and pathological cellular processes, including cancer, where
they can act as oncogenes or tumor suppressor genes. Recently, lowered expression of miR-100, resulting in upregulation
of FGFR3, has been correlated with low-grade, non-invasive bladder urothelial cancer, as an alternative oncogenesis
pathway to the typical FGFR3 gene mutation. Our aim is to analyze the role of miR-100 in bladder cancer cell
lines in controlling the expression of some of its possible target genes, including FGFR3 and its relationship with
proliferation, apoptosis and DNA ploidy.
Methods: The bladder cancer cell lines RT4 and T24 were transfected with pre-miR 100, anti-miR 100 and their
respective controls using a lipid-based formulation. After transfection mRNA and protein levels of its supposed
target genes THAP2, BAZ2A, mTOR, SMARCA5 and FGFR3 were analyzed by quantitative real time polymerase
chain reaction (qRT-PCR) and western blotting. Cell proliferation, apoptosis and DNA ploidy were analyzed by
flow cytometry. For statistical analysis, a t-test was applied, p < 0.05 was considered significant.
Results: After miR-100 transfection, there was a significant reduction in the mRNA of mTOR (p = 0.006),
SMARCA5 (p = 0.007) and BAZ2A (p = 0.029) in RT4, mTOR (p = 0.023) and SMARCA5 (p = 0.015) in T24. There
was a reduction in the expression of all proteins, variable from 22.5% to 57.1% in both cell lines. In T24 miR-100
promoted an increase in cell proliferation and anti-miR 100 promoted apoptosis characterizing miR-100 as an
oncomiR in this cell line representative of a high-grade urothelial carcinoma.
Conclusion: miR-100 transfection reduces expression of BAZ2A, mTOR and SMARCA5 mRNA and protein in BC
cell lines. miR-100 would be classified as an oncomiR in T24 cells representative of high grade urothelial carcinoma
promoting increase in cell proliferation and reduction in apoptosis. The knowledge of miRNA role in tumors will allow
their use as tumor markers and targets for new therapies.
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MicroRNAs (miRNAs) are a class of small non-coding
RNAs, approximately 19 to 22 nucleotides in length
that are important in the regulation of gene expression
[1]. At present, approximately 1,600 human miRNAs
have been identified by sequence analysis (miRBase)
[2], and it is believed that miRNAs regulate approxi-
mately 30% of all human genes [3]. Aberrant expres-
sion patterns and functional abnormalities of miRNAs
are implicated in several human diseases, including
cancer [4]. They play important roles in the regulation
of cellular processes, such as proliferation, apoptosis
and differentiation. Recent evidences suggest that miR-
NAs are context and cell-dependent and behave differ-
ently depending on the tumor type or tumor stage [4].
We have recently demonstrated that miR-100 is under-
expressed in 100% of low-grade, non-invasive bladder
cancers, with FGFR3 as a putative target gene [5], repre-
senting a possible first step of tumorigenesis, before the
typical FGFR3 mutation. There are other proposed target
genes of miR100 that could be involved in bladder car-
cinogenesis, such as THAP2, BAZ2A, SMARCA5 and
mTOR. Our aim is to study the role of miR-100 in bladder
cancer cell lines in controlling the expression of mRNAs
and proteins of its putative target genes and its relation-
ship with proliferation, apoptosis and DNA ploidy.Methods
Cell culture
The human bladder cancer cell line RT4 was obtained
from the European Collection of Cell Cultures (ECACC)
and was cultured in McCoy’s medium supplemented
with 20% fetal bovine serum with a 1% antibiotic/
antimycotic solution (Sigma Co., St. Louis, MO, USA) at
37°C in an atmosphere of 5% CO2. The human bladder
cancer cell line T24 was kindly provided by Prof. Daisy
Salvadori (Unesp, Botucatu, SP, Brazil) and was main-
tained as described above.miR-100 and anti-miR 100 cell transfection
The cells were seeded in 24-well plates at a concen-
tration of 5.0 × 104/well for miRNA and anti-miRNA
transfection. The reverse-transfections into the blad-
der cell lines were carried out in Opti-MEM I using
cationic liposomes (Lipofectamine 2000; Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
protocol. Synthetic miR-100 (Catalog number AM17100 –
Assay ID PM 10188), anti-miR 100 (Catalog number
AM17000 – Assay ID AM 10188) and their respective
scrambled controls, control miR (ctrl miR; catalog
number AM17110) and control anti-miR (ctrl αmiR;
catalog number AM17010), were purchased from
Ambion (Austin, TX, USA). The negative controlsand the miRNAs were used at a final concentration of
50 nM.
RNA extraction and quantitative real-time PCR (qRT-PCR)
The RNA extraction was performed using the mirVana
kit (Ambion, Austin, TX, USA) according to the manu-
facturer’s instructions. RNA concentrations were deter-
mined by 260/280 nm absorbance using a Nanodrop®
ND-1000 spectrophotometer (Thermo Scientific). For
cDNA synthesis, 200 ng of total RNA was reverse tran-
scribed using random primers and Multiscribe reverse
transcriptase (Applied Biosystems, Foster City, CA,
USA) with incubation at 25°C for 10 min, followed by
37°C for 120 min and 85°C for 5 min. To determine
the expression of the mRNAs for THAP2, BAZ2A,
mTOR, SMARCA5 and FGFR3, qRT-PCR was performed
using TaqMan assays from Applied Biosystems (Foster
City, CA, USA). All samples were amplified in a 7500 fast
real-time PCR system (Applied Biosystems, Foster City,
CA, USA). The samples were processed at 50°C for
2 min, followed by 95°C for 10 min and 40 thermal cy-
cles of 95°C for 15 seconds and 60°C for 1 min. The
reactions were conducted in duplicate, and human ß2
microglobulin was used as an internal endogenous control.
The relative expression level of the mRNAs was calculated
by the 2-ΔΔCt method. The data shown are representative
of three independent experiments.
Western blotting
For western blotting, T24 and RT4 cells (2,5 × 105 cells/
well) were transfected with 50 nM of pre-miR 100, anti-
miR 100, or their respective controls. After 48 h, the
cells were resuspended and lysed in their wells using
RIPA buffer and protease inhibitor (Millipore, Billerica,
MA, USA). Protein concentrations were established
using the Pierce 660 nm Protein Assay (Thermo Scientific).
From the cell lysate, 30 μg of protein was electrophoresed
on a 12% SDS-polyacrylamide gel. After electrophoresis, the
protein was transferred to a PVDF Immobilon-P membrane
(Millipore, Billerica, MA, USA). The membrane was blocked
in Tris-buffered saline (TBS) containing 1% BSA (bovine
serum albumin) (Sigma, St. Louis, MO, USA) and 1%
Tween-20 for 15 sec at room temperature. The 20-min pri-
mary antibody incubation occurred in a SNAP camera
(Millipore) following the manufacturer’s instructions. The
primary antibodies used were: mTOR (Abcam 1:500),
FGFR3 (Abcam 1:600), SMARCA5 (Abcam 1:2000), BAZ2A
(Abcam 1:500) and THAP2 (Proteintech 1:600). β-actin
(Millipore 1:500) was used as a control. The secondary anti-
body was used at a 1:5000 dilution with an incubation time
of 20 min (Millipore) in the same equipment. Protein
expression analysis was performed using Alliance 4.7
equipment (Uvitec, Cambridge, UK) running the soft-
ware package Alliance 16.06.
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cytometry
For analysis of DNA ploidy, cell cycle and apoptosis the
cells T24 and RT4 were transfected with pre-miR 100,
anti-miR 100 and their respective controls as described
above, and after 96 hours of transfection, cells were
fixed in 70% ethanol, stained with propidium iodide
(PI) diluted in PBS (200 μg/ml, RNAse A 20 mg/ml,
triton X-100 and PBS pH 7.4) for 15 min at 37°C. The
apoptosis was measured using the Annexin V Apop-
tosis Detection Kit I (BD Biosciences, USA) according
the instructions of the manufacturer’s. RT4 and T24
cells (1 × 105 cells per well) were seeded in a 12-well
plate and after 96 hours of transfection they were har-
vested and stained with annexin-V-FITC and PI. The
analyses of DNA ploidy, cell cycle and apoptosis were
performed using the FlowJo (Tree Star) version 10 and
FlowJo version 7.6.1 (Three Star). The results were expressed
as mean ± SEM.
Statistical analysis
For statistical analysis, experiments were performed in
triplicate. With GraphPad Prism version 5 software Stu-
dent’s t-test was used to calculate the difference in ex-
pression of target genes, cell proliferation and apoptosis,
and p < 0.05 was considered significant.
Results
RT4 cells exposed to pre-miR 100 showed a significant re-
duction in mRNA expression of mTOR (53%, p = 0.006),
SMARCA5 (69.6%, p = 0.007) and BAZ2A (53%, p = 0.029).
THAP2 reduction could be considered marginal (31.4%,
p = 0.053). FGFR3 mRNA expression decreased 20.6%
but did not reach statistical significance compared to
the control (p = 0.28). When exposed to anti-miR 100,
we observed an increase in the expression of all genes, but
the increase was significant only for THAP2 and BAZ2A,
with increases of 23.8% (p = 0.03) and 32% (p = 0.004),
respectively (Figure 1).
T24 cells showed a significant reduction in the expres-
sion of mTOR (30.7%, p = 0.02) and SMARCA5 (39.2%,
p = 0.01) after exposure to pre-miR 100. The other four
genes also showed decreased, but non-significant, ex-
pression relative to the controls. When exposed to anti-
miR 100, all genes except SMARCA5 showed enhanced,
but non-significant, expression relative to the controls
(Figure 2).
The western blot analysis of the proteins encoded by
the genes THAP2, BAZ2A, mTOR, SMARC5 and FGFR3
in RT4 and T24 bladder cancer cells exposed to pre-miR
100, anti-miR 100 or their respective controls is shown in
Figures 3 and 4. We observed a decrease in protein levels,
ranging from 30.8% to 49.6% in RT4 cells and 22.5% to
57.1% in T24 cells. The largest decreases in expressionwere observed for SMARCA5 (49.6%) and FGFR3 (40.5%)
in RT4 cells and mTOR (57.1%), SMARCA5 (51.7%) and
FGFR3 (46.9%) in T24 cells.
For RT4 cell line there was no difference in cell prolif-
eration comparing transfected cells with pre-miR 100,
anti-miR-100 and their negative controls. In T24 cell line
exposed to pre-miR 100 44.5% of the cells were in G2/S
or M versus 36% in the control. Although this difference
was not statistically different (p = 0.37), there was an
increase of 8.5% in cell proliferation after miR-100 trans-
fection. There was no differences in the number of cells
in apoptosis in both cell lines after miR-100 transfection.
However, when T24 cells were exposed to anti-miR 100
there was an increase of 13% in cells in apoptosis,
although this difference was not significant (p = 0.642)
(Table 1).
The DNA ploidy is usually expressed as the DNA
index (DI), that is, the ratio G0/G1 peak mean fluores-
cence of the tumor and the G0/G1 peak of the reference
diploid (2n) population. There was no alteration in DNA
ploidy in cell lines RT4 and T24 after transfection of
pre-miR 100 and anti-miR 100.
Discussion
This study investigated the regulation of putative target
genes of miR-100 in two bladder urothelial cancer cell
lines representatives of low (RT4) and high (T24) grade
tumors. After miR-100 transfection, we observed a reduc-
tion in mRNA expression of the genes of interest, but the
reduction was significant only for mTOR, BAZ2A and
SMARCA5. Declines in protein levels were also detected.
The functional significance of miR-100 in cancer biol-
ogy is supported by recent studies that show change in
its expression in several types of cancer. Downregulation
of miR-100 has been described in several tumors, such
as squamous cell carcinoma of the tongue and oral cav-
ity [6,7], nasopharyngeal cancer [8], hepatocellular car-
cinoma [9], hepatoblastomas [10] and serous ovarian
carcinoma [11]. Overexpression of miR100 has been ob-
served in medulloblastomas [12], and gastric [13], pan-
creatic [14] and prostate cancers [15].
In bladder urothelial cancer, our group and others
have shown that the downregulation of miR-100 is char-
acteristic of low-grade, non-invasive carcinomas and is
thought to be an alternative pathway to the FGFR3 mu-
tation typical of this type of tumor [16,17]. FGFR3 is a
putative target of miR-100 and was previously shown to
downregulate the gene expression by Luciferase reporter
assay [18]. In our assays, we observed a reduction in
FGFR3 mRNA expression of 20.6% in RT4 cells and 28%
in T24 cells, which was not statistically significant com-
pared to controls. However, there was a reduction in the
protein expression by 40.5% in RT4 cells and 46.9% in
T24 cells, leading us to conclude that miR-100 plays a
Figure 1 mRNA expression of FGFR3, mTOR, BAZ2A, SMARCA5 and THAP2 after transfection of the RT4 low grade urothelial bladder
cancer cell line with miR-100 and anti-miR 100.
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high grade urothelial carcinomas. FGFR3 mutation is the
most common phenomenon in low-grade non-invasiveurothelial carcinomas, described in 70% of the cases and
identified as a molecular marker of non-aggressive dis-
ease [19,20]. Catto was the first to associate miR-100
Figure 2 mRNA expression of FGFR3, mTOR, BAZ2A, SMARCA5 and THAP2after transfection of the T24 high grade urothelial bladder
cancer cell line with miR-100 and anti-miR 100.
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cancer, proposing that miR-100 loss could precede the
FGFR3 mutation [18]. In this context, miR-100 could beconsidered as a tumor suppressor miRNA because it
regulates the activity of the tyrosine kinase receptor
FGFR3.
Figure 3 mTOR, FGFR3, THAP2, SMARCA5 and BAZ2A protein expression in RT4 bladder cancer cells, evaluated by western blotting,
after exposure to miR-100.
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100 transfection were SMARCA5 and mTOR. There was
a significant reduction in the expression of both mRNA
and protein.
mTOR (mammalian target of rapamycin) is a serine-
threonine protein kinase, which acts with PI3K, AKT
and the tumor suppressor gene PTEN to form a signal-
ing pathway involved in the regulation of protein synthe-
sis, cell growth, proliferation, survival, apoptosis, and
angiogenesis [21]. Deregulation of the mTOR pathwayFigure 4 mTOR, FGFR3, THAP2, SMARCA5 and BAZ2A protein express
after exposure to miR-100.has been related to oncogenesis in several malignancies,
including bladder cancer [22]. Our data show that the
mTOR gene was downregulated by miR-100 in bladder
cancer cell lines. There was a significant reduction in
mTOR mRNA expression and a strong reduction of
mTOR protein expression in the T24 Cell Line (57.1%).
This result suggests again that miR100 is a tumor sup-
pressor miRNA because it downregulates the important
PI3K/AKt/mTOR pathway. The same result was recently
described by Xu et al., who identified miR-100 as aion in T24 bladder cancer cells, evaluated by western blotting,
Table 1 Percentage of cells in phases G1, S and G2 / M
and apoptosis in RT4 and T24 cell lines examed by flow
cytometry
miR-100 miR-control Anti-miR-100 Anti-miR-
control
Cell Line RT4
G1(%) 58 61 58 52
S(%) 8 7 8 8
G2/M(%) 32 32 34 34
Apoptosis(%) 57 59 60.5 62
Cell Line T24
G1(%) 56.5 64 59 59
S(%) 12.5 6 8 9
G2/M(%) 32 30 33 32
Apoptosis(%) 62 64 39 26
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part at least through repression of mTOR [23].
SMARCA5 (hSNF2H) is a member of the SWI/SNF
family involved in both homologous and non-homologous
end joining recombination required for efficient DNA re-
pair [24-26]. In this context, miR-100 should act as an
oncomiR because the downregulation of SMARCA5 could
result in deficiencies in DNA repair that could promote
chromosomal instability, a hallmark of high-grade bladder
cancer.
Other genes are also putative targets of miR-100 and
could be important in the bladder carcinogenesis process.
The Thanatos-associated protein (THAP) DNA-binding
domain is a conserved C2CH zinc-finger motif shared by
a large family of cellular factors with functions associated
with cell-proliferation and cell cycle control. The function
of THAP2 is not well known, but THAP1 has been de-
scribed as an inhibitor of the cell cycle, interfering with
pRb/E2F [27]. Others suggest that THAP proteins could
play a major role in targeting genes to promote tran-
scription regulation through interactions with protein
complexes associated with chromatin remodeling [28].
Another role of THAP2 is associated with apoptosis,
which, together with the transcription repressor protein
Par-4 (prostate-apoptosis-response-4; a pro-apoptotic fac-
tor that suppresses the expression of BCL2, an important
inhibitor of apoptosis), facilitates the process of pro-
grammed cell death [29]. Therefore, repression of THAP2
by miR-100 could affect apoptosis in urothelial cancer.
We detected a 31.4% reduction in THAP2 mRNA in RT4
cells and a 24.2% reduction in T24 cells, the reduction in
THAP2 protein expression was 29.8% in RT4 cells and
22.5% in T24 cells. The T24 cell line is a high-grade
urothelial carcinoma, where the loss of function of tumor
suppressor genes, such as p53 and Rb, and chromosomal
instability are typical. In this context, miR-100 would actas an oncomiR because it downregulates THAP2, a puta-
tive tumor suppression protein that is important for Rb
function, apoptosis induction and DNA chromatin remod-
eling [27,30,31].
In RT4 cells, BAZ2A was lowered after miR-100 trans-
fection. BAZ2A, also known as TIP5 and WALp3, func-
tions with the SWI/SNF family member SNF2h to form
the NoRC (nucleolar remodeling complex). This com-
plex induces nucleosome sliding, which is important for
transcription regulation [32].
It is reasonable to think that the down expression of
miR-100 that we previously observed in low-grade, non-
invasive bladder urothelial cancer is related to the lack
of control of mTOR and FGFR3 and to the maintenance
of genomic stability due to not interfering with SMARCA5.
In more aggressive urothelial cancers, miR-100 was related
to increase in cell proliferation and its inhibition promoted
increase in apoptosis. The decrease in expression of
SMARCA5 and BAZ2A that we also identified in this
lineage may primarily be influencing chromosomal sta-
bility that is a characteristic of this tumor, nevertheless
no change occurred after inhibition or transfection of
the miRNA. The observation of the behavior in gene
and protein expression in human cancer cell lines through-
out miRNAs exposure would bring a new knowledge that
will permit their use as tumor markers and targets for
treatment.
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